“The pause in AstraZeneca's COVID-19 vaccine trial shows it is a 'well-run' trial,” World Health Organisation (WHO) said in a statement on Tuesday.
The WHO, further, said that the pause showed that they have looked at safety in 'an appropriate manner'.
Last week, AstraZeneca and the University of Oxford announced that they had stopped the key phase 3 trials of a coronavirus vaccine after a participant was found to have an inflammatory syndrome that affects the spinal cord.
Over the weekend, the British pharma company said that they have been given a go-ahead to restart the vaccine trials in the UK.
The market mood is already upbeat and therefore the comments from WHO add to the optimism.
AstraZeneca plc is gaining 2.50% to regain 8,600 levels, at the time of writing.
S&P 500 futures rally 0.68%, approaching the 3,400 mark. AUD/USD trades close to weekly tops of 0.7336, up 0.51% on the day.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.